MedPath

Chimerix

πŸ‡ΊπŸ‡ΈUnited States
Ownership
-
Employees
72
Market Cap
$88M
Website
Introduction

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.

Clinical Trials
Related News

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

Phase 3
Recruiting
Conditions
H3 K27M
Glioma
Interventions
Other: Placebo
First Posted Date
2022-10-14
Last Posted Date
2025-06-06
Lead Sponsor
Chimerix
Target Recruit Count
450
Registration Number
NCT05580562
Locations
πŸ‡ΊπŸ‡Έ

Barrow Neurological Institute, Phoenix, Arizona, United States

πŸ‡ΊπŸ‡Έ

Banner MD Anderson Cancer Center, Phoenix, Arizona, United States

πŸ‡ΊπŸ‡Έ

Phoenix Childrens Hospital, Phoenix, Arizona, United States

and more 155 locations

Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects

Phase 1
Completed
Conditions
Hepatic Impairment
Interventions
First Posted Date
2022-05-26
Last Posted Date
2022-05-26
Lead Sponsor
Chimerix
Target Recruit Count
25
Registration Number
NCT05391724
Locations
πŸ‡ΊπŸ‡Έ

Elite Research, Miami, Florida, United States

πŸ‡ΊπŸ‡Έ

Orlando Clinical Research Center, Orlando, Florida, United States

πŸ‡ΊπŸ‡Έ

DaVita Clinical Research, Minneapolis, Minnesota, United States

Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas

Conditions
Glioma
First Posted Date
2022-05-26
Last Posted Date
2022-05-26
Lead Sponsor
Chimerix
Registration Number
NCT05392374
Locations
πŸ‡ΊπŸ‡Έ

University of California San Francisco, San Francisco, California, United States

πŸ‡ΊπŸ‡Έ

Children's Hospital Colorado, Aurora, Colorado, United States

πŸ‡ΊπŸ‡Έ

Children's National Medical Center, Washington, District of Columbia, United States

and more 7 locations

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

Conditions
Glioma
H3 K27M
First Posted Date
2020-11-05
Last Posted Date
2025-06-04
Lead Sponsor
Chimerix
Registration Number
NCT04617002
Locations
πŸ‡ΊπŸ‡Έ

BMDACC at Banner University Medical Center Phoenix, Phoenix, Arizona, United States

πŸ‡ΊπŸ‡Έ

Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States

πŸ‡ΊπŸ‡Έ

Children's Hospital of Orange County, Orange, California, United States

and more 20 locations

Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia

Phase 3
Terminated
Conditions
Acute Myeloid Leukemia
Interventions
Drug: Dociparstat
Other: Control
First Posted Date
2020-10-01
Last Posted Date
2024-04-15
Lead Sponsor
Chimerix
Target Recruit Count
9
Registration Number
NCT04571645
Locations
πŸ‡ΊπŸ‡Έ

UC Irvine Medical Center, Orange, California, United States

πŸ‡ΊπŸ‡Έ

University of Kansas Cancer Center, Westwood, Kansas, United States

πŸ‡ΊπŸ‡Έ

Norton Cancer Institute, St. Matthews Campus, Louisville, Kentucky, United States

and more 11 locations

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Phase 1
Recruiting
Conditions
Central Nervous System Neoplasms
Pilocytic Astrocytoma
Ependymoma
Neuroectodermal Tumors, Primitive
Glioblastoma
Anaplastic Pleomorphic Xanthoastrocytoma
Gliomatosis Cerebri
Teratoid Rhabdoid Tumor
Anaplastic Astrocytoma
Oligodendroglioma
Interventions
First Posted Date
2020-09-09
Last Posted Date
2025-02-07
Lead Sponsor
Chimerix
Target Recruit Count
102
Registration Number
NCT04541082
Locations
πŸ‡ΊπŸ‡Έ

National Institutes of Health, Bethesda, Maryland, United States

Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure

Phase 2
Terminated
Conditions
Acute Lung Injury
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Coronavirus Disease 2019 (COVID-19)
Interventions
Drug: Placebo
First Posted Date
2020-05-15
Last Posted Date
2022-08-30
Lead Sponsor
Chimerix
Target Recruit Count
27
Registration Number
NCT04389840
Locations
πŸ‡ΊπŸ‡Έ

University of Alabama at Birmingham, Birmingham, Alabama, United States

πŸ‡ΊπŸ‡Έ

Advanced Pulmonary Research Institute/Wellington Regional Medical Center, Loxahatchee Groves, Florida, United States

πŸ‡ΊπŸ‡Έ

Augusta University, Augusta, Georgia, United States

and more 9 locations

Incidence and Outcomes Associated With the Management of Adenovirus Infections in Allogenic Hematopoietic Cell Transplant Recipients

Completed
Conditions
Adenovirus Infections, Human
First Posted Date
2020-02-26
Last Posted Date
2022-03-25
Lead Sponsor
Chimerix
Target Recruit Count
216
Registration Number
NCT04285788

An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola

Phase 2
Withdrawn
Conditions
Ebola Virus Disease
Interventions
First Posted Date
2020-02-13
Last Posted Date
2020-02-26
Lead Sponsor
Chimerix
Registration Number
NCT04268966

Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia

Phase 2
Withdrawn
Conditions
Adenovirus
Interventions
Drug: Standard of Care
First Posted Date
2018-05-22
Last Posted Date
2021-07-21
Lead Sponsor
Chimerix
Registration Number
NCT03532035
Locations
πŸ‡ΊπŸ‡Έ

UCLA Medical Center, Los Angeles, California, United States

πŸ‡ΊπŸ‡Έ

University of Chigago, Chicago, Illinois, United States

πŸ‡ΊπŸ‡Έ

Brigham and Womens Hospital, Boston, Massachusetts, United States

and more 5 locations
Β© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy